Novel cancer therapies: Treatments driven by tumour biology

Postgraduate Medical Journal

Volumn 89, Issue 1057, 2013, Pages 652-658

  Ramaswami, Ramya ^a   Harding, Victoria ^a   Newsom Davis, Thomas ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PANITUMUMAB; PLACEBO; PREDNISOLONE; SCATTER FACTOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; VASCULOTROPIN; VEMURAFENIB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ALLERGIC REACTION; ANAPHYLAXIS; ANGIOGENESIS; ANOREXIA; ARTHRALGIA; BIOLOGY; BLEEDING; BREAST CANCER; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DRUG TARGETING; ELECTROLYTE DISTURBANCE; FLUID RETENTION; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOSS OF APPETITE; LUNG CANCER; LUNG COMPLICATION; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUTH PAIN; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHENOTYPE; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; STOMACH CANCER; THYROID DISEASE; VENOUS THROMBOEMBOLISM; VOMITING; CHROMOSOME 22; CHROMOSOME 9; DRUG DELIVERY SYSTEM; DRUG EFFECTS; IMMUNOTHERAPY; MICROBIOLOGY; NEOPLASMS; PROTO ONCOGENE; VACCINATION; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; DRUG DELIVERY SYSTEMS; GENES, ERBB-1; GENES, ERBB-2; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TOR SERINE-THREONINE KINASES; VACCINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885759905     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2012-131533     Document Type: Review

References (45)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol (Meeting Abstracts) 2007;25:4000.
3. Van Cutsem E, Kohne C-L, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
4. Bonner JA, Harari PM, Girait J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
5. D Roock W, DeVriendt V, Normanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12:594-603.
6. Fukuoka M, Wu Y-L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomised, open-label, first-line study of Gefitinib versus Carboplatin/Paclitaxel in clinically selscted patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74.
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
8. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
9. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overepresses HER2. N Engl J Med 2001;344:783-92.
11. Smith I, Procter M, Gelber RD, et al. 2 year follow-up of trastuzumab after adjucant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
12. Miller K, Wang M, Gralow J, et al. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med 2007;357:2666-76.
13. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
14. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30.
15. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 2007;356:2271-81.
16. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
17. Ferrara N, Hillan KJ, Gerber H-P, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev Drug Discov 2004;3:391-400.
18. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clinical Therapeutics 2006;28:1779-802.
19. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
21. Vredenburgh JJ, Desjardins A, Herdon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol, 2007;30:4722-9.
22. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356:115-24.
23. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
24. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL positive leukaemia treated with imatinib in a single centre: a 4.5 year follow-up. Cancer 2005;103:1659-69.
25. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) treated with imatinib. ASH, 2009.
26. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 2010;363:1693-703.
27. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
28. Chapman PB, Hauschild A, Robert C, et al. Improved survival with Vemurafenib in Melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
29. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
30. Davis ID. An overview of cancer immunotherapy. Immunol Cell Biol 2000;78:179-95.
31. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010;37:533-46.
32. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
33. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
34. Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002;62:7075.
35. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
36. Kantoff PW, Higano CS, Shore ND, et al. IMPACT Study Investigators, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
37. Attard G, Reid A, Yap TA, et al. Phase I Clinical Trial of a selective inhibitor of CYP17, Abiraterone Acetate, confirms that Castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71.
38. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
39. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
40. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutics inhibitors of the c-met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14.
41. Petak I, Schwab R, Orfi L, et al. Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drugs Discovery 2010;9:523-35.
42. Wistuba II, Gelovani JG, Jacoby JJ, et al. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 2011;8:135-41.
43. Kim S, Herbst RS, Wistuba II, et al. The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discovery 2011;1:OF43-51.
44. Cragg MS, Harris C, Strasser A, et al. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009;9:321-6.
45. Gasparini G, Longo R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4:605-15.